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The Heart Estrogen Replacement Study (HERS) was the first 
large clinical trial to assess in post-menopausal women whether 
estrogen plus progesterone, or estrogen alone in women without a 
uterus, reduced cardiovascular (CV) events.1 HERS was a secondary 
prevention trial, but it was quickly followed by the Women’s Health 
Initiative (WHI), for primary prevention.2 There were those who thought
that these studies were unethical, because observational cohort 
studies had consistently shown that hormone replacement therapy 
(HRT) not only reduced CV events,3 but also bestowed other benefits, 
including protection against osteoporosis and dementia.4 HRT 
improved surrogate CV outcomes such as lipoprotein levels and 
endothelial function.5 
She was one of the first patients that we recruited into HERS at 
our site in Hartford, Connecticut. She arrived fashionably but 
conservatively dressed, self-confident, and outgoing. “I told my 
cardiologist that he must refer me for your trial. Women have been left
out of research studies for too long. I want to do this for my daughter, 
and my grandchildren too if I ever have any!” She was 67 years old, a 
senior executive at a major insurance company, and was used to being
in charge. In addition to her job she worked as a volunteer at Hands on
Hartford, a food bank, and was a fundraiser for the hospital. She had 
had a coronary angioplasty 3 years before, but had no other relevant 
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history. Her CV risk factors were controlled, she exercised regularly, 
and she followed a near vegetarian diet.
When I get to the very end of taking a history from a new 
patient, after inquiring about work, and how they spend their time, I 
usually ask “What do you do for fun?” I have found that this question 
often provides me with useful insight into what makes my patient tick. 
Often I hear back a rueful “I don’t have fun any more!” To which the 
follow-up question is “What did you used to do for fun?” And then the 
patient may turn to the spouse and say wistfully “Remember the 
summer when the kids were in high school and we took them camping 
in Algonquin Park?” Or something.
I asked her.
“I masturbate,” she said, and explained: “My husband died 
several years ago, and I found that I really miss physical contact. I 
have a friend now, and we get along quite well, but he doesn’t like to 
be touched. He was hospitalized recently, and I was standing at his 
bedside. I wanted to reach out and hug him, or at least hold his hand, 
but I didn’t.”
The HERS steering committee, consisting of the study leadership 
and the principal investigator from each of the 20 clinical sites, met at 
the end of the study for the unveiling of the results. As with any trial, 
everyone hoped that the treatment would prove to be beneficial. 
Additionally, many of the steering committee members had spent a 
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significant part of their career studying HRT. Even beyond that, HRT 
was different from an ordinary drug; along with the trial participants, 
many believed that this could be a treatment unique to women, 
perhaps to partially compensate for past neglect. After all, it was called
HERS.
The results? Overall HRT had no effect on the primary endpoint, 
non-fatal MI or CHD death, despite an 11% lower LDL-C and 10% 
higher HDL-C in the HRT group. Despite the lack of effect overall, there
was a statistically significant increase in the primary endpoint in the 
HRT group during the first year, and a significant decrease in these CV 
events during years 4 and 5. Because of this potential late benefit, 
follow-up was continued, with women who had been taking HRT 
requested to continue it, and women who had been taking placebo 
cautioned to avoid it, due to the increased risk during the first year.6 
I saw my patient for the last time at her 6-year visit. Medically, 
not much had changed. She had experienced 2 mini-strokes that had 
left no obvious damage, and she had no recurrence of coronary 
symptoms. She had retired from her job. She didn’t drive much any 
more, and her daughter accompanied her. She looked different 
compared to her first visit; she was casually dressed with no make-up, 
and her hair was now its natural gray color. She acted differently as 
well; the vivacity was gone, she moved slowly, and answered questions
as if they were a burden. I noticed an antidepressant among her list of 
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medications. I asked about her friend. “He has been sick a lot lately. I 
don’t see him much any more.”
The saddest feature of HERS was the downward course that so 
many women followed. Few had major CV events, and hardly any died,
but cancers, fractures, and other medical events were common. Many 
were widowed during follow-up, and others shouldered important 
caregiver roles as husbands and other family members developed 
chronic illnesses. Many worked well beyond retirement age because of 
financial necessity. Grandmothers were conscripted to act as mothers 
because their children could not. These outcomes had nothing to do 
with HRT. My patient, cushioned financially and with a supportive 
family, was far from the worst off.
Even with the robust social safety net available in Canada, the 
numbers are stacked against older women. Women marry on average 
men who are 2 years older, and live on average 4.3 years longer (men 
79.3, women 83.6 years).7 As a consequence, 62.7% of women are part
of a couple in their late 60’s, but only 10.4% are by age 85 or older; 
the corresponding statistics for men are 77.9% and 46.2%.7 Because 
women earn less during their careers than men, and because they are 
more likely to leave the workforce to have children, they have 
accumulated less wealth and are more likely to live in poverty in old 
age.
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Medically, more than 1/3 of Canadian women aged 65 and older 
report that they are usually in pain, compared to approximately ¼ of 
men.7 Half of women in this age group suffer from hypertension. 
Cardiac conditions that are difficult to treat, such as heart failure with 
preserved systolic function, Takotsubo cardiomyopathy, and 
spontaneous coronary artery dissection, are far more common in 
women than men.
At the end of her last appointment, my patient and her daughter 
thanked me for having looked after her. I again expressed my regrets 
that HRT did not have a benefit for women like her. I shook the 
daughter’s hand. I turned to my patient. I resisted an impulse to reach 
out and hug her. I shook her hand and said good-bye, knowing that 
really, she had already departed, gradually, over the years.
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